John C. Reed, M.D., Ph.D. Executive Vice President Pharmaceuticals, R&D Johnson & Johnson Neil Davie, Ph.D. Head, Late Development Cardiovascular, Metabolism & Pulmonary Hypertension Ruxandra Draghia-Akli, M.D., Ph.D. Global Head
Find the Janssen portfolio of long-acting injections (LAIs) for schizophrenia treatment in adults. See full Prescribing & Safety Info, including Boxed WARNING.
KG (King Pharmaceuticals) Happy New Year to all, Pete Earle Paolo Pezzutti enters: If I may humbly add my 2 cents: - bearish on S&P: 900 in dec - crisis in Europe will bring EURUSD down to 1.15 - gold will remain a safe have haven: up to 1500 - big winner: natural gas to ...
Janssen Pharmaceuticals, Inc. (Titusville, NJ, US) International Classes: A61K47/64;A61K39/108;A61K47/02;A61K47/20;A61K47/26;A61K47/65;C08B37/00 View Patent Images: Download PDF 20210275681 Primary Examiner: GANGLE, BRIAN J Attorney, Agent or Firm: ...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Janssen Pharmaceuticals, Inc., (Janssen) has entered into an agreement with Arrowhead Pharmaceuticals, Inc., (Arrowhead) for an exclusive, worldwide license to develop and commercialize ARO-HBV, a Phase 1/2 subcutaneous,...
, Aug. 19, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies fo...
Worldwide Chairman, Pharmaceuticals,Johnson & Johnson. “We’re excited by the opportunity to further advance patient care by combiningJohnson & Johnson’s world-class R&D, commercial and supply chain capabilities with Momenta’s talented people,...
actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals Inc., and/orJohnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, includin...
She will lead the strategic development and execution of patient-centered research and engagement from within Janssen Scientific and Medical Affairs and with partners across North America Pharmaceuticals and Janssen. Previously, Lisa spent four years leading the strategy and operations for the Integrated ...